Mutations in Lynch syndrome genes MSH6 and PMS2 may be associated with breast cancer
Full article: https://www.nature.com/articles/gim2017254
Some women with mutations in MSH6 and PMS2, two Lynch syndrome genes, may have a modest (2 to 3-fold) increased risk for breast cancer. (6/14/18 updated 09/25/19)
Questions To Ask Your Health Care Provider
- Should I consider genetic counseling or genetic testing for Lynch syndrome mutations given my personal and family history?
- My family has a history of Lynch syndrome, should I consider genetic counseling and testing?
- As a Lynch syndrome mutation carrier, what breast cancer screening options should I consider? What are my risks for other cancers?
- As a Lynch syndrome mutation carrier, what preventive measures should I consider?
- Can you refer me to a genetics expert?
Open Clinical Trials
The following screening and prevention studies are open to people with Lynch syndrome.
- NCT03805919: Men at High Genetic Risk for Prostate Cancer. This is a prostate cancer screening study using MRI in high-risk men. This study is open to men with Lynch syndrome and other mutations.
- NCT05129605: Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS). This study will look at how well prostate MRI works as a screening tool for men at high risk for prostate cancer. This study is open to men with an inherited mutation in ATM, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C, RAD51D, TP53 and other genes.
- NCT02206360: Pancreatic Cancer Early Detection Program. This pancreatic cancer screening study uses esophageal ultrasound to screen for pancreatic cancer in high-risk people. The study is open to people who have a family history of pancreatic cancer and an MLH1 mutation or other mutation linked to increased cancer risk.
- NCT03568630: Blood Markers of Early Pancreas Cancer. This pancreatic cancer study involves blood samples taken over time to look for biomarkers of pancreatic cancer in high-risk people. The study is open to people with an MLH1 mutation or other mutation linked to increased cancer risk.
- NCT03250078: A Pancreatic Cancer Screening Study in Hereditary High-Risk Individuals. The main goal of this study is to screen and detect pancreatic cancer and precursor lesions in individuals with a strong family history or genetic predisposition to pancreatic cancer. MRI and magnetic cholangiopancreatography (MRI/MRCP) will be utilized to screen for early-stage pancreatic lesions.
Other clinical trials for patients with endometrial cancer can be found here.
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.